Safety of high-carbohydrate fluid diet 2 h versus overnight fasting before non-emergency endoscopic retrograde cholangiopancreatography : A single-blind, multicenter, randomized controlled trial
Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license..
BACKGROUND: Although overnight fasting is recommended prior to endoscopic retrograde cholangiopancreatography (ERCP), the benefits and safety of high-carbohydrate fluid diet (CFD) intake 2 h before ERCP remain unclear. This study aimed to analyze whether high-CFD intake 2 h before ERCP can be safe and accelerate patients' recovery.
METHODS: This prospective, multicenter, randomized controlled trial involved 15 tertiary ERCP centers. A total of 1330 patients were randomized into CFD group (n = 665) and fasting group (n = 665). The CFD group received 400 mL of maltodextrin orally 2 h before ERCP, while the control group abstained from food/water overnight (>6 h) before ERCP. All ERCP procedures were performed using deep sedation with intravenous propofol. The investigators were blinded but not the patients. The primary outcomes included postoperative fatigue and abdominal pain score, and the secondary outcomes included complications and changes in metabolic indicators. The outcomes were analyzed according to a modified intention-to-treat principle.
RESULTS: The post-ERCP fatigue scores were significantly lower at 4 h (4.1 ± 2.6 vs. 4.8 ± 2.8, t = 4.23, P <0.001) and 20 h (2.4 ± 2.1 vs. 3.4 ± 2.4, t = 7.94, P <0.001) in the CFD group, with least-squares mean differences of 0.48 (95% confidence interval [CI]: 0.26-0.71, P <0.001) and 0.76 (95% CI: 0.57-0.95, P <0.001), respectively. The 4-h pain scores (2.1 ± 1.7 vs. 2.2 ± 1.7, t = 2.60, P = 0.009, with a least-squares mean difference of 0.21 [95% CI: 0.05-0.37]) and positive urine ketone levels (7.7% [39/509] vs. 15.4% [82/533], χ2 = 15.13, P <0.001) were lower in the CFD group. The CFD group had significantly less cholangitis (2.1% [13/634] vs. 4.0% [26/658], χ2 = 3.99, P = 0.046) but not pancreatitis (5.5% [35/634] vs. 6.5% [43/658], χ2 = 0.59, P = 0.444). Subgroup analysis revealed that CFD reduced the incidence of complications in patients with native papilla (odds ratio [OR]: 0.61, 95% CI: 0.39-0.95, P = 0.028) in the multivariable models.
CONCLUSION: Ingesting 400 mL of CFD 2 h before ERCP is safe, with a reduction in post-ERCP fatigue, abdominal pain, and cholangitis during recovery.
TRAIL REGISTRATION: ClinicalTrials.gov, No. NCT03075280.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Chinese medical journal - (2023) vom: 24. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Wenbo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT03075280 Citation Status Publisher |
|---|
| doi: |
10.1097/CM9.0000000000002820 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361185820 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361185820 | ||
| 003 | DE-627 | ||
| 005 | 20240324234758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CM9.0000000000002820 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM361185820 | ||
| 035 | |a (NLM)37620294 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meng, Wenbo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of high-carbohydrate fluid diet 2 h versus overnight fasting before non-emergency endoscopic retrograde cholangiopancreatography |b A single-blind, multicenter, randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03075280 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. | ||
| 520 | |a BACKGROUND: Although overnight fasting is recommended prior to endoscopic retrograde cholangiopancreatography (ERCP), the benefits and safety of high-carbohydrate fluid diet (CFD) intake 2 h before ERCP remain unclear. This study aimed to analyze whether high-CFD intake 2 h before ERCP can be safe and accelerate patients' recovery | ||
| 520 | |a METHODS: This prospective, multicenter, randomized controlled trial involved 15 tertiary ERCP centers. A total of 1330 patients were randomized into CFD group (n = 665) and fasting group (n = 665). The CFD group received 400 mL of maltodextrin orally 2 h before ERCP, while the control group abstained from food/water overnight (>6 h) before ERCP. All ERCP procedures were performed using deep sedation with intravenous propofol. The investigators were blinded but not the patients. The primary outcomes included postoperative fatigue and abdominal pain score, and the secondary outcomes included complications and changes in metabolic indicators. The outcomes were analyzed according to a modified intention-to-treat principle | ||
| 520 | |a RESULTS: The post-ERCP fatigue scores were significantly lower at 4 h (4.1 ± 2.6 vs. 4.8 ± 2.8, t = 4.23, P <0.001) and 20 h (2.4 ± 2.1 vs. 3.4 ± 2.4, t = 7.94, P <0.001) in the CFD group, with least-squares mean differences of 0.48 (95% confidence interval [CI]: 0.26-0.71, P <0.001) and 0.76 (95% CI: 0.57-0.95, P <0.001), respectively. The 4-h pain scores (2.1 ± 1.7 vs. 2.2 ± 1.7, t = 2.60, P = 0.009, with a least-squares mean difference of 0.21 [95% CI: 0.05-0.37]) and positive urine ketone levels (7.7% [39/509] vs. 15.4% [82/533], χ2 = 15.13, P <0.001) were lower in the CFD group. The CFD group had significantly less cholangitis (2.1% [13/634] vs. 4.0% [26/658], χ2 = 3.99, P = 0.046) but not pancreatitis (5.5% [35/634] vs. 6.5% [43/658], χ2 = 0.59, P = 0.444). Subgroup analysis revealed that CFD reduced the incidence of complications in patients with native papilla (odds ratio [OR]: 0.61, 95% CI: 0.39-0.95, P = 0.028) in the multivariable models | ||
| 520 | |a CONCLUSION: Ingesting 400 mL of CFD 2 h before ERCP is safe, with a reduction in post-ERCP fatigue, abdominal pain, and cholangitis during recovery | ||
| 520 | |a TRAIL REGISTRATION: ClinicalTrials.gov, No. NCT03075280 | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Leung, Joseph W |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhenyu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qiyong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Leida |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xuefeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Yingmei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jijun |e verfasserin |4 aut | |
| 700 | 1 | |a Yue, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Kexiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xiaoliang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Senlin |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Kailin |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Haiping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Songming |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zhiqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qingyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Bendong |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Tiemin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yingkai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lichao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Zilong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Long |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhengfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiajia |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Xiaowen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fangzhao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lingen |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Mingzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Mi, Ningning |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xianzhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Wence |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jinqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Azumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Kiyohito |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jiankang |e verfasserin |4 aut | |
| 700 | 1 | |a Nur, Ula |e verfasserin |4 aut | |
| 700 | 1 | |a Weiderpass, Elisabete |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chinese medical journal |d 1979 |g (2023) vom: 24. Aug. |w (DE-627)NLM000002755 |x 2542-5641 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:24 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CM9.0000000000002820 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 24 |c 08 | ||